Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients

AIDS

Volumn 15, Issue 8, 2001, Pages 991-998

  Baede van Dijk, Patricia A ^a,c   Hugen, Patricia W H ^b   Verweij van Wissen, Corrien P W G M ^b   Koopmans, Peter P ^b   Burger, David M ^b   Hekster, Yechiel A ^b  

^a MEDICINES EVALUATION BOARD   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Kinesis Holding BV   (Netherlands)

Author keywords

M8 metabolite; Nelfinavir; Pharmacokinetics; Therapeutic Drug Monitoring

Indexed keywords

CYTOCHROME P450 3A4; DRUG METABOLITE; NELFINAVIR; OMEPRAZOLE;

ADULT; AGED; ARTICLE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INTOXICATION; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ARYL HYDROCARBON HYDROXYLASES; BODY WEIGHT; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, FACTUAL; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; ENZYME INHIBITORS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NELFINAVIR; OMEPRAZOLE;

EID: 0035947339     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200105250-00007     Document Type: Article

References (21)

1. 1. Jarvis B, Faulds D, Nelfinavir, a review of its therapeutic efficacy in HIV infection. Drugs 1998, 56:147-167.
2. 2. Pai VB, Nahata MC. Nelfinavir mesylate: a protease inhibitor. Ann Pharmacother 1999, 33:325-339.
3. 3. Sandoval TM, Grettenberger HM, Zhang KE et al. Metabolism of nelfinavir mesylate, an HIV-1 protease inhibitor by human liver microsomes and recombinant human isoforms. XII Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists. San Francisco, November 1998 [abstract 1096].
4. 4. Lillibridge JH, Lee CA, Pithavala YK et al. The role of polymorphic CYP2C19 in the metabolism of nelfinavir mesylate. XII Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists. San Francisco, November 1998 [abstract 3035].
5. 5. Zhang K, Wu E, Patick A et al. Plasma metabolites of nelfinavir, a potent HIV protease inhibitor, in HIV positive patients: Quantitation by LC-MS/MS and antiviral activities. 6th European ISSX meeting. Gothenburg, Sweden, June 1997 [abstract 128].
6. 6. Hugen PWH, Verweij-van Wissen CPWGM, Burger DM, Wuis EW, Koopmans PP, Hekster YA. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir, and ritonavir in human plasma by reversed-phase high performance liquid chromatography. J Chromatogr B, Biomed Sci Appl 1999, 727:139-149.
7. 7. Jeppesen U, Rasmussen BB, Brosen K. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 1997, 62:279-286.
8. 8. Suri A, Bramer SL. Effect of omeprazole on the metabolism of cilostazol. Clin Pharmacokinet 1999, 37(Suppl 2):53-59.
9. 9. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K, Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996, 51:73-78.
10. 10. Petersen A, Johnson M, Nelson M, Peters B, Opravil M, Clendeninn N. Long-term comparison of BID and TID dosing of nelfinavir (NFV) in conbination with stavudine (d4T) and lamivudine (3TC) in HIV patients. XII International Conference on AIDS. Geneva, June 1998 [abstract 12224].
11. 11. Hugen PWH, Burger DM, Aarnoutse RE, Baede P, Nieuwkerk PT, Hekster YA. Concentration ratios of protease inhibitors (PIs) can be applied to assess non-compliance. First International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, the Netherlands, March 2000 [abstract 3.1].
12. 12. Khaliq Y, Gallicano K, Sequin I et al. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. Br J Clin Pharmacol 2000, 50:108-115.
13. 13. Hsyu PH, Lillibridge JH, Beeby S, Schultz MD, Heine PR, Kerr BM. Pharmacokinetics of nelfinavir and metabolite M8 in patients with liver impairment after a single oral 750 mg dose of Viracept®. First International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, the Netherlands, March 2000 [abstract 8.3].
14. 14. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999, 9:539-549.
15. 15. Xie HG, Kim RB, Stein CM, Wilkinson GR, Wood AJ. Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent. Br J Clin Pharmacol 1999, 48:402-408.
16. 16. Xie HG, Xu ZH, Luo X, Huang SL, Zeng FD, Zhou HH. Genetic polymorphisms of debrisoquine and S-mephenytoin oxidation metabolism in Chinese populations: a meta-analysis. Pharmacogenetics 1996, 6:235-238.
17. 17. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996, 31:9-28.
18. 18. Malaty L, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Safety 1999, 20:147-169.
19. 19. Zhang MH, Pithavala YK, Lee CA et al. Apparent genetic polymorphism in nelfinavir metabolism: evaluation of clinical relevance. 12th International Symposium on Microsomes and Drug Oxidation. Montpelier, France, July 1998 [abstract 264].
20. 20. Jackson KA, Rosenbaum SE, Kerr DM, Pithavala YK, Yuen G, Dudley MN. A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial. Antimicrob Agents Chemother 2000, 44:1832-1837.
21. 21. Roche Registration Ltd UK. Viracept® (nelfinavir). Summary of Product Characteristics, March 2000.